top of page


New Book: No Cure for Me
I wrote No Cure for Me as a long-time survivor of pulmonary hypertension. Knowing that I may be one of Canada’s longest survivors, it sparked a thought—what if one day I became the world’s longest survivor? I’ve set my sights on living to 103, and along the way, I couldn’t help but imagine how remarkable it would be to earn a place in the Guinness World Records. That idea—part hope, part determination—became the seed for this thriller. Writing it was my way of blending realit
Carolyn Mathur, Patient
1 day ago1 min read


A New PAH Education Course for Better Patient Care
Pulmonary arterial hypertension (PAH) patient Nicole Dempsey was involved in developing a new online Continuing Medical Education course, PAH in Practice: A Case-based Online Learning Program for Better Patient Care, alongside pulmonary hypertension experts Dr. Steeve Provencher, Dr. Kristina Kemp, and Dr. Rhea Varughese. This type of training is an important step forward in improving awareness and understanding of this rare condition: because PAH symptoms can be nonspecific
Nicole Dempsey, Patient
5 days ago2 min read
Biomarkers identified for high-altitude PH
This study looked at which proteins and metabolic biomarkers might be associated with the development of high-altitude pulmonary hypertension (PH). Looking at data from China, from rat tissues, and from the UK biobank, the researchers identified four proteins and 11 metabolites and built what they describe as a "robust predictive model" to predict and prevent high-altitude pulmonary hypertension. Read the Journal of Cardiovascular Development and Disease article
Robyn Kalda
5 days ago1 min read


Canadian PH researchers identify a gene leading to heart failure in PAH
This week is Heart Failure Awareness Week. As this year's awareness campaign says, it's not normal to be breathless! Heart failure is, unfortunately, one of the consequences of pulmonary hypertension. The right side of the heart can adapt for a while by getting thicker and stronger, but it's hard to tell why it eventually starts to fail, and this happens at different times for different patients. Raising awareness about this serious condition is important: early detection hel

PHA Canada
May 72 min read


Mental Health Week: Let’s Come Together
May 4-10 is Mental Health Week in Canada, and the theme is “Come Together, Canada.” PHA Canada Knowledge Philanthropist Lisa Harder talks about the meaning of connection. This year’s theme for Mental Health Week is all about the importance of connectedness in our overall well-being. Both social connections and connection with ourselves helps to foster resilience and to reduce the sense of isolation we may feel (Canadian Mental Health Association, 2026). While we can recogn
Lisa Harder
May 63 min read
Alberta Lagging in Access to Rare Disease Innovation
Calgary/Edmonton, AB (May 4, 2026) The Pulmonary Hypertension Association of Canada (PHA Canada), along with expert physicians, are calling on Alberta to fund sotatercept (Winrevair), a new treatment for pulmonary arterial hypertension (PAH). “Pulmonary arterial hypertension is a rare, universally fatal disease involving high blood pressure in the blood vessels of the lungs, putting stress on the right side of the heart. This causes heart failure, shortness of breath with min

PHA Canada
May 33 min read
Smoking delays PAH diagnosis, but not CTEPH
Researchers looked at whether cigarette smoking affected the diagnosis and disease progression of patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). They found that smoking tended to delay the diagnosis of PAH but not CTEPH. They also found that male smokers with PAH fared worse than female smokers. Read the Pulmonology article
Robyn Kalda
Apr 271 min read


Positive results from a pair of clinical trials
Two companies have announced good results from clinical trials in the past few weeks. Merck’s Phase 2 proof-of-concept CADENCE trial of two different doses of sotatercept for some Group 2 pulmonary hypertension patients succeeded. Trial participants had combined post- and precapillary pulmonary hypertension and heart failure with preserved ejection fraction (CpcPH-HFpEF). Participants who received sotatercept showed significant improvements in their pulmonary vascular resista

PHA Canada
Apr 221 min read
Environmental triggers may contribute to heritable PAH
This study tried to identify new environmental triggers or genetic causes in heritable pulmonary arterial hypertension. They found several potential genes for further exploration, but they also found consistent toxin exposure on one of the families they were investigating. They conclude that environmental triggers should also be investigated in heritable PAH. Read the Scientific Reports article
Robyn Kalda
Apr 131 min read


Thank you, caregivers!
April 7 is National Caregiver Day Many pulmonary hypertension patients have caregivers, whether they’re the partners, parents, or children of patients. Caregivers make a major difference in patients’ lives, helping them manage their pulmonary hypertension and daily routines. Nearly half of patients with pulmonary arterial hypertension rely on the help of a caregiver, underscoring just how essential this support truly is. Caregivers often take on a wide range of responsibiliti

PHA Canada
Apr 61 min read
Time to diagnosis matters for patients with PAH
This study identified factors associated with a delayed diagnosis of PAH and found that earlier diagnosis (<6 months) and treatment initiation were associated with significantly improved survival. More early diagnosis patients saw a pulmonologist before another provider. Read the Pulmonary Circulation article
Robyn Kalda
Mar 301 min read
Review finds selexipag is well tolerated in children
A review of 12 studies evaluating selexipag in pediatric patients with pulmonary arterial hypertension found that it improved functional capacity and mPAP, especially when added to existing therapies. About 60% of pediatric patients had side effects, mostly mild. Read the Pediatric Cardiology article
Robyn Kalda
Mar 161 min read


Celebrating women in pulmonary hypertension research
This International Women’s Day, let’s take a moment to recognize and celebrate women in all aspects of pulmonary hypertension research: women who agree to participate in clinical trials, women who are researchers, and women who are on health care teams at clinics where research takes place. In the past, it wasn’t unusual for women to be left out of clinical trials, particularly women of childbearing age. Because women were excluded from research studies, we don’t fully unders

PHA Canada
Mar 51 min read


Nourish to Flourish! It’s Nutrition Month
March is National Nutrition month, and again the Dietitians of Canada have chosen Nourish to Flourish as the theme, highlighting “highlights the profound connections between food and overall well-being, emphasizing the transformative role of nutrition in our lives”. It’s a good reminder that the everyday choices we make around food can have a big impact on how we feel. Nutrition can be top of mind for people with pulmonary hypertension, who often need to keep a low-sodium di

PHA Canada
Mar 42 min read


A tale of two drug trials
Two companies have announced the results of clinical trials of drugs for pulmonary arterial hypertension recently, neatly illustrating successful and unsuccessful results. Last week, Gossamer Bio announced that their drug, seralutinib, failed to meet the primary endpoint of its phase 3 PROSERA clinical trial . Gossamer’s stock price dropped precipitously. Interestingly, one of the reasons the study failed may have been an unusually good response to the placebo in some locatio

PHA Canada
Mar 41 min read
Sotatercept might help treat portopulmonary hypertension
Patients with portopulmonary hypertension were not included in clinical trials for sotatercept. This case report found that sotatercept helped one patient with portopulmonary hypertension, who was then able to get a liver transplant. However, they did note some risks. Read the Communications Medicine article
Robyn Kalda
Mar 21 min read


Friends: good for your heart
Pulmonary hypertension patients are at risk of heart failure, and conversely, heart failure patients are at risk of developing pulmonary hypertension. This Heart Month , we’re posting tips for keeping your heart strong and healthy. We’re learning more about how important social connections are—not only for our mental health, but for our physical health too! Loneliness and social isolation increase the risk of heart attacks and stroke . Social connections are so important for

PHA Canada
Feb 231 min read


What I’d Tell My Newly Diagnosed CTEPH Self
What would you say to yourself at the moment everything changed? In this honest and inspiring talk, Derek Henderson of Toronto reflects on what he would tell his newly diagnosed self after learning he had CTEPH in 2012. From the shock of no longer being able to bike to undergoing PEA (PTE) surgery and adapting to lifelong blood thinners, Derek shares a journey shaped by resilience, humor, and hard-earned perspective. Guided by his motto — “If you’re going to be a duck, lea

PHA Canada
Feb 191 min read


Exercise – for your heart
Pulmonary hypertension patients are at risk of heart failure, and conversely, heart failure patients are at risk of developing pulmonary hypertension. This Heart Month , we’re posting tips for keeping your heart strong and healthy. Everyone knows that exercise is good for your heart, and research shows it’s generally safe for pulmonary hypertension patients . But did you know that recent research found that switching up your exercise, instead of always doing the same workout

PHA Canada
Feb 181 min read


Living, Grieving, and Leaving a Legacy
Living Grief Like many of you, I was raised in a culture where death was darkness, morose and devastating. When we wore black and spoke in hushed tones around the topic, bit never directly about it. IT... the word was taboo. Analogies of "going to sleep forever" and "crossing over to a better place" made the subject unattainable. My arm’s length relationship with death shrouded its mystery in a dark cloak. And then, at 37 years young, I learned that PAH was taking over. I h
Angèle Belliveau, Patient
Feb 174 min read
bottom of page
